Loading candles…
Corona Remedies Limited, incorporated in August 2004, is an Indian pharmaceutical company engaged in developing, manufacturing, and marketing pharmaceutical products. The company focuses on domestic formulations primarily in therapeutic areas including women’s healthcare, cardiology, pain management, urology, and chronic healthcare. Its business segments reflect these key healthcare domains, with an emphasis on the chronic and women’s healthcare markets. Corona Remedies has undertaken organic brand building and strategic acquisitions of brands and portfolios from global pharmaceutical companies. The company operates within the pharmaceutical industry in India but does not have any listed subsidiaries or public exchange listings reported.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and recommend final dividend, if any, on the equity shares of the Company f… | 11 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 2 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 2 Jan 2026 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.